Clinical trials: Moderate to Severe Dementia
Dementia, Dementia, Vascular
Advanced Cognitive Stimulation Therapy Hong Kong (ACST-HK)
This study is a feasibility randomized controlled trial (RCT) for an evidence-based intervention for people with moderate to severe dementia in Hong Kong.
- Conditions
- Dementia, Dementia, Vascular, Dementia, Mixed, Dementia With Lewy Bodies
- Trial name
- NCT04555629
- Testing
- Advanced Cognitive Stimulation Therapy Hong Kong
- Volunteers
- 32 people
- Sponsor
- University College, London
Alzheimer Disease
Vielight Neuro RX Gamma - Feasibility Pilot
This study tests the effects of the Neuro RX Gamma synchronous and asynchronous devices on the cognitive and behavioral functioning of subjects with moderate-to-severe Alzheimer's Disease.
- Trial name
- NCT03328195
- Testing
- Neuro RX Gamma synchronous, Neuro RX Gamma asynchronous
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Vielight Inc.
Alzheimer's Disease
An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease
About 65% of patients with severe Alzheimer's Disease (AD) will have symptoms of agitation. There are drawbacks associated with the currently available therapeutic interventions for agitation associated with Alzheimer's Disease.
- Trial name
- NCT00097916
- Testing
- memantine HCl
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- Forest Laboratories
Breast Cancer, Chronic Myeloproliferative Disorders
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
RATIONALE: Alemtuzumab and glucocorticoids, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00410657
- Testing
- alemtuzumab, methylprednisolone, prednisone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Alzheimer's Disease
Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease
The primary objective of the study was to examine the safety and tolerability of memantine in outpatients with moderate to severe Alzheimer's Disease.
- Trial name
- NCT00857233
- Testing
- Memantine
- Where
- 33 sites in Canada
- Volunteers
- 297 people
- Sponsor
- H. Lundbeck A/S
Alzheimer Disease, Lewy Body Dementia (LBD)
Deep Cervical Lymphaticovenous Anastomosis Surgery for Moderate-to-Advanced Dementia Patients
This clinical trial aims to evaluate the clinical efficacy and safety of Deep Cervical Lymphaticovenous Anastomosis (DLVA) in patients aged 50-80 with moderate to severe neurodegenerative dementia.
- Conditions
- Alzheimer Disease, Lewy Body Dementia (LBD), Frontotemporal Dementia (FTD), Dementia
- Trial name
- NCT06978946
- Testing
- Deep Cervical Lymphaticovenous Anastomosis(DLVA)
- Where
- China
- Volunteers
- 85 people
- Sponsor
- RenJi Hospital
Alzheimer's Disease, Dementia
Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease
This study will evaluate the pharmacological efficacy on language capability and compliance with combination of new Ebixa oral pump and donepezil compared to donepezil only in patients with probable Alzheimer's disease.
- Trial name
- ROMEO-AD (NCT01849042)
- Testing
- Ebixa, donepezil
- Where
- South Korea
- Volunteers
- 188 people
- Sponsor
- Konkuk University Medical Center
Alzheimer's Disease
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).
- Trial name
- NCT00679627
- Testing
- Galantamine
- Where
- 95 sites in Czechia, Estonia and 10 more
- Volunteers
- 2,051 people
- Sponsor
- Janssen Research & Development, LLC
Parkinson's Disease Dementia
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
The purpose of this study is to provide long-term safety data for rivastigmine capsule and transdermal patch treatments, in particular the effect of rivastigmine on worsening of the underlying motor symptoms of Parkinson's…
- Trial name
- NCT00623103
- Testing
- Rivastigmine capsule, Rivastigmine transdermal patch
- Where
- 127 sites in United States, Argentina and 11 more
- Volunteers
- 583 people
- Sponsor
- Novartis
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Alzheimer's Disease
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.
- Trial name
- NCT01766336
- Testing
- Group 1 ELND005, Group 2 ELND005
- Where
- 46 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- OPKO Health, Inc.
Dementia
Exploratory Study of the Effects of Peptide PMS-001 on Long-Delay Recall in Patients With Moderate to Severe Dementia
This is a single-center, randomized, double-blind, placebo-controlled study. Patients will be randomly assigned to either the peptide intervention group (with dose escalation at 15mg, 30mg, 60mg, and 75mg) or the placebo control…
- Trial name
- NCT06946511
- Testing
- Peptide PMS-001 Intravenous Injection
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Moderate to Severe Alzheimer's Disease
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
The objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients with moderate to severe Alzheimer's disease (AD).
- Trial name
- NCT05303701
- Testing
- GV1001 1.12mg
- Volunteers
- 750 people
- Sponsor
- Samsung Pharmaceutical Co., Ltd.
Alzheimer's Disease, Dementia
Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients
The primary aim is to determine whether Divalproex ER or one of the atypical antipsychotics is more effective improving dementia related behavioral symptoms in patients with dementia, and evaluate the impact of such improvements…
- Conditions
- Alzheimer's Disease, Dementia, Behavioral Symptoms
- Trial name
- NCT00375557
- Testing
- Divalproex ER, Quetiapine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Cincinnati
Alzheimer's Disease
An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of dimebon in subjects with moderate-to-severe Alzheimer's Disease.
- Trial name
- NCT01066546
- Testing
- Dimebon tablet for oral administration
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Pfizer
Moderate to Severe Alzheimer's Disease
Donepezil and Memantine in Moderate to Severe Alzheimer's Disease
The trial will examine whether pharmacological treatment with donepezil, memantine or combination of memantine and donepezil is any better than a placebo (dummy) treatment in people with Alzheimer's disease who have reached the…
- Trial name
- DOMINO-AD (NCT00866060)
- Testing
- Memantine, Donepezil
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- King's College London
Dementia
A Study to Compare Genetic Variations of IGF-I and IGF-II
The purpose of this study is to determine if insulin-like growth factors (IGF) play a role in the development of dementia, specifically Alzheimer's disease (AD).
- Trial name
- NCT01329523
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Avera McKennan Hospital & University Health Center
Alzheimer's Disease
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
This is Phase 3 study, multi-centre, double-blind, placebo controlled, parallel group to evaluate the effects of AC-SD-03 on the efficacy and safety among participants with mild to moderate Alzheimer's Disease.
- Trial name
- NCT04187547
- Testing
- Tricaprilin
- Sponsor
- Cerecin
Alzheimer's Disease
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
This is a prospective, multicenter, open-label study. Following screening and baseline assessments, eligible patients will be switched to rivastigmine and will enter the 16 week run-in rivastigmine treatment phase.
- Trial name
- NCT00234637
- Testing
- Rivastigmine, memantine
- Where
- France
- Volunteers
- 204 people
- Sponsor
- Novartis
Alzheimer's Disease
Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of long-term administration of 23 milligram (mg) donepezil sustained release (SR) in participants with moderate to severe Alzheimer's disease.
- Trial name
- NCT00566501
- Testing
- Donepezil
- Where
- United States
- Volunteers
- 915 people
- Sponsor
- Eisai Inc.